<?xml version='1.0' encoding='utf-8'?>
<document id="29247736"><sentence text="Metabolic Pathway of Icotinib In Vitro: The Differential Roles of CYP3A4, CYP3A5, and CYP1A2 on Potential Pharmacokinetic Drug-Drug Interaction." /><sentence text="Icotinib is the first self-developed small molecule drug in China for targeted therapy of non-small cell lung cancer"><entity charOffset="0-8" id="DDI-PubMed.29247736.s2.e0" text="Icotinib" /></sentence><sentence text=" To date, systematic studies on the pharmacokinetic drug-drug interaction of icotinib were limited" /><sentence text=" By identifying metabolite generated in human liver microsomes and revealing the contributions of major cytochromes P450 (CYPs) in the formation of major metabolites, the aim of the present work was to understand the mechanisms underlying pharmacokinetic and pharmacological variability in clinic" /><sentence text=" A liquid chromatography/UV/high-resolution mass spectrometer method was developed to characterize the icotinib metabolites"><entity charOffset="103-111" id="DDI-PubMed.29247736.s5.e0" text="icotinib" /></sentence><sentence text=" The formation of 6 major metabolites was studied in recombinant CYP isozymes and human liver microsomes with specific inhibitors to identify the CYPs responsible for icotinib metabolism" /><sentence text=" The metabolic pathways observed in vitro are consistent with those observed in human" /><sentence text=" Results demonstrated that the metabolites are predominantly catalyzed by CYP3A4 (77%∼87%), with a moderate contribution from CYP3A5 (5%∼15%) and CYP1A2 (3" /><sentence text="7%∼7" /><sentence text="5%)" /><sentence text=" The contribution of CYP2C8, 2C9, 2C19, and 2D6 is insignificant" /><sentence text=" Based on our observations, to minimize drug-drug interaction risk in clinic, coprescription of icotinib with strong CYP3A inhibitors or inducers must be weighed" /><sentence text=" CYP1A2, a highly inducible enzyme in the smoking population, may also represent a determinant of pharmacokinetic and pharmacological variability of icotinib, especially in lung cancer patients with smoking history"><entity charOffset="149-157" id="DDI-PubMed.29247736.s13.e0" text="icotinib" /></sentence><sentence text="" /></document>